Dolutegravir Resistance in Malawi's National HIV Treatment Program.
Africa
HIV
Malawi
antiretroviral therapy
dolutegravir
resistance
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
21
12
2021
accepted:
04
04
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020-September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity.
Identifiants
pubmed: 35493118
doi: 10.1093/ofid/ofac148
pii: ofac148
pmc: PMC9045949
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac148Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
N Engl J Med. 2019 Aug 29;381(9):816-826
pubmed: 31339676
N Engl J Med. 2019 Aug 29;381(9):887-889
pubmed: 31461601
PLoS One. 2011;6(11):e28184
pubmed: 22132237
Lancet Infect Dis. 2019 Jul;19(7):e246-e252
pubmed: 30902440
Public Health Action. 2019 Dec 21;9(4):169-173
pubmed: 32042610
Intervirology. 2012;55(2):98-101
pubmed: 22286876
J Antimicrob Chemother. 2019 Nov 1;74(11):3135-3149
pubmed: 31280314
N Engl J Med. 2021 Jul 22;385(4):330-341
pubmed: 34289276
Nat Commun. 2020 Dec 1;11(1):5922
pubmed: 33262331
AIDS Res Ther. 2020 May 20;17(1):22
pubmed: 32434561
Antivir Ther. 2016;21(3):253-9
pubmed: 26562173
J Virol Methods. 2008 Nov;153(2):176-81
pubmed: 18706932
J Infect Dis. 2022 Feb 1;225(3):364-366
pubmed: 34282844
N Engl J Med. 2019 Aug 29;381(9):803-815
pubmed: 31339677
J Infect Dis. 2014 Aug 1;210(3):354-62
pubmed: 24446523